ID VRK3_HUMAN Reviewed; 474 AA.
AC Q8IV63; A6NEG5; A8KA53; Q502Y2; Q9P2V8;
DT 10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT 10-OCT-2003, sequence version 2.
DT 27-MAR-2024, entry version 186.
DE RecName: Full=Serine/threonine-protein kinase VRK3;
DE EC=2.7.11.22;
DE AltName: Full=Vaccinia-related kinase 3;
GN Name=VRK3;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC TISSUE=Liver;
RA Nezu J.;
RT "Vaccinia related kinase 3 (VRK3).";
RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA Ni X., Xie Y., Mao Y.;
RT "Cloning and characterization of a novel human VRK3 gene.";
RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC TISSUE=Testis, and Trachea;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15057824; DOI=10.1038/nature02399;
RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA Rubin E.M., Lucas S.M.;
RT "The DNA sequence and biology of human chromosome 19.";
RL Nature 428:529-535(2004).
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC TISSUE=Brain, and Skin;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [6]
RP FUNCTION, SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL.
RX PubMed=14645249; DOI=10.1074/jbc.m310813200;
RA Nichols R.J., Traktman P.;
RT "Characterization of three paralogous members of the Mammalian vaccinia
RT related kinase family.";
RL J. Biol. Chem. 279:7934-7946(2004).
RN [7]
RP INTERACTION WITH RAN.
RX PubMed=18617507; DOI=10.1074/mcp.m700586-mcp200;
RA Sanz-Garcia M., Lopez-Sanchez I., Lazo P.A.;
RT "Proteomics identification of nuclear Ran GTPase as an inhibitor of human
RT VRK1 and VRK2 (vaccinia-related kinase) activities.";
RL Mol. Cell. Proteomics 7:2199-2214(2008).
RN [8]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55 AND SER-59, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA Elledge S.J., Gygi S.P.;
RT "A quantitative atlas of mitotic phosphorylation.";
RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN [9]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82; SER-83 AND SER-90, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Leukemic T-cell;
RX PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA Rodionov V., Han D.K.;
RT "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT reveals system-wide modulation of protein-protein interactions.";
RL Sci. Signal. 2:RA46-RA46(2009).
RN [10]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82 AND SER-83, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT site occupancy during mitosis.";
RL Sci. Signal. 3:RA3-RA3(2010).
RN [11]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-82; SER-83; SER-115 AND
RP SER-122, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT "System-wide temporal characterization of the proteome and phosphoproteome
RT of human embryonic stem cell differentiation.";
RL Sci. Signal. 4:RS3-RS3(2011).
RN [12]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54; SER-59 AND SER-83, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma, and Erythroleukemia;
RX PubMed=23186163; DOI=10.1021/pr300630k;
RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA Mohammed S.;
RT "Toward a comprehensive characterization of a human cancer cell
RT phosphoproteome.";
RL J. Proteome Res. 12:260-271(2013).
RN [13]
RP FUNCTION, MUTAGENESIS OF LYS-203, AND CATALYTIC ACTIVITY.
RX PubMed=25899223; DOI=10.1016/j.bbamcr.2015.04.007;
RA Park C.H., Ryu H.G., Kim S.H., Lee D., Song H., Kim K.T.;
RT "Presumed pseudokinase VRK3 functions as a BAF kinase.";
RL Biochim. Biophys. Acta 1853:1738-1748(2015).
RN [14]
RP FUNCTION, PHOSPHORYLATION AT SER-108, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP SER-108, AND INTERACTION WITH DUSP3.
RX PubMed=27346674; DOI=10.1038/srep28634;
RA Song H., Kim W., Choi J.H., Kim S.H., Lee D., Park C.H., Kim S., Kim D.Y.,
RA Kim K.T.;
RT "Stress-induced nuclear translocation of CDK5 suppresses neuronal death by
RT downregulating ERK activation via VRK3 phosphorylation.";
RL Sci. Rep. 6:28634-28634(2016).
RN [15]
RP FUNCTION, AND INTERACTION WITH HSP70/HSPA1A AND DUSP3.
RX PubMed=27941812; DOI=10.1038/srep38452;
RA Song H., Kim W., Kim S.H., Kim K.T.;
RT "VRK3-mediated nuclear localization of HSP70 prevents glutamate
RT excitotoxicity-induced apoptosis and Abeta accumulation via enhancement of
RT ERK phosphatase VHR activity.";
RL Sci. Rep. 6:38452-38452(2016).
RN [16]
RP UBIQUITINATION BY RNF144A, AND SUBCELLULAR LOCATION.
RX PubMed=33067254; DOI=10.1242/jcs.247304;
RA Han S.H., Kim K.T.;
RT "RNF144a induces ERK-dependent cell death under oxidative stress via
RT downregulation of vaccinia-related kinase 3.";
RL J. Cell Sci. 133:0-0(2020).
RN [17]
RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 146-474, FUNCTION, AND LACK OF
RP CATALYTIC ACTIVITY.
RX PubMed=19141289; DOI=10.1016/j.str.2008.10.018;
RA Scheeff E.D., Eswaran J., Bunkoczi G., Knapp S., Manning G.;
RT "Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a
RT highly conserved kinase fold, and a putative regulatory binding site.";
RL Structure 17:128-138(2009).
RN [18]
RP VARIANTS [LARGE SCALE ANALYSIS] PHE-59; THR-105; LEU-171; LEU-268; TYR-288;
RP CYS-370 AND GLY-371.
RX PubMed=17344846; DOI=10.1038/nature05610;
RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA Futreal P.A., Stratton M.R.;
RT "Patterns of somatic mutation in human cancer genomes.";
RL Nature 446:153-158(2007).
CC -!- FUNCTION: Plays a role in the regulation of the cell cycle by
CC phosphorylating the nuclear envelope protein barrier-to-autointegration
CC factor/BAF that is required for disassembly and reassembly,
CC respectively, of the nuclear envelope during mitosis (PubMed:25899223).
CC Under normal physiological conditions, negatively regulates ERK
CC activity along with VHR/DUSP3 phosphatase in the nucleus, causing
CC timely and transient action of ERK. Stress conditions activate CDK5
CC which phosphorylates VRK3 to increase VHR phosphatase activity and
CC suppress prolonged ERK activation that causes cell death
CC (PubMed:27346674). For example, upon glutamate induction, promotes
CC nuclear localization of HSP70/HSPA1A to inhibit ERK activation via
CC VHR/DUSP3 phosphatase (PubMed:27941812). {ECO:0000250|UniProtKB:Q8K3G5,
CC ECO:0000269|PubMed:14645249, ECO:0000269|PubMed:19141289,
CC ECO:0000269|PubMed:25899223, ECO:0000269|PubMed:27346674,
CC ECO:0000269|PubMed:27941812}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC Evidence={ECO:0000269|PubMed:25899223};
CC -!- SUBUNIT: Interacts with DUSP3 (PubMed:27346674, PubMed:27941812).
CC Interacts with RAN. Interacts with HSP70/HSPA1A (PubMed:27941812).
CC {ECO:0000250, ECO:0000269|PubMed:18617507,
CC ECO:0000269|PubMed:27941812}.
CC -!- INTERACTION:
CC Q8IV63; P61244: MAX; NbExp=2; IntAct=EBI-1058605, EBI-751711;
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14645249,
CC ECO:0000269|PubMed:27346674, ECO:0000269|PubMed:33067254}. Cytoplasm
CC {ECO:0000269|PubMed:33067254}. Note=Under oxidative stress, migrates
CC from the nucleus to the cytoplasm. {ECO:0000269|PubMed:33067254}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=Q8IV63-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q8IV63-2; Sequence=VSP_008544, VSP_008545;
CC Name=3;
CC IsoId=Q8IV63-3; Sequence=VSP_043409;
CC -!- PTM: Phosphorylated at Ser-108 by CDK5; leading to protection of the
CC cell against H2O2-induced apoptosis. {ECO:0000269|PubMed:25899223}.
CC -!- PTM: Ubiquitinated by RNF144A. {ECO:0000269|PubMed:33067254}.
CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC protein kinase family. VRK subfamily. {ECO:0000305}.
CC -!- CAUTION: Inactive as a kinase due to its inability to bind ATP.
CC {ECO:0000305|PubMed:19141289}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AB031052; BAA90769.1; -; mRNA.
DR EMBL; AF514788; AAP47180.1; -; mRNA.
DR EMBL; AK292918; BAF85607.1; -; mRNA.
DR EMBL; AK303010; BAG64141.1; -; mRNA.
DR EMBL; AC011452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC023556; AAH23556.1; -; mRNA.
DR EMBL; BC095449; AAH95449.1; -; mRNA.
DR CCDS; CCDS12791.1; -. [Q8IV63-1]
DR CCDS; CCDS33076.1; -. [Q8IV63-3]
DR CCDS; CCDS77334.1; -. [Q8IV63-2]
DR RefSeq; NP_001020949.1; NM_001025778.1. [Q8IV63-3]
DR RefSeq; NP_001295349.1; NM_001308420.1. [Q8IV63-2]
DR RefSeq; NP_057524.3; NM_016440.3. [Q8IV63-1]
DR RefSeq; XP_005259028.1; XM_005258971.3. [Q8IV63-1]
DR RefSeq; XP_005259029.1; XM_005258972.3. [Q8IV63-3]
DR RefSeq; XP_006723300.1; XM_006723237.3. [Q8IV63-1]
DR RefSeq; XP_006723301.1; XM_006723238.3. [Q8IV63-3]
DR RefSeq; XP_011525325.1; XM_011527023.2.
DR PDB; 2JII; X-ray; 2.00 A; A/B=146-474.
DR PDBsum; 2JII; -.
DR AlphaFoldDB; Q8IV63; -.
DR SMR; Q8IV63; -.
DR BioGRID; 119394; 144.
DR IntAct; Q8IV63; 27.
DR MINT; Q8IV63; -.
DR STRING; 9606.ENSP00000469880; -.
DR ChEMBL; CHEMBL3430761; -.
DR GlyGen; Q8IV63; 2 sites, 1 O-linked glycan (2 sites).
DR iPTMnet; Q8IV63; -.
DR PhosphoSitePlus; Q8IV63; -.
DR BioMuta; VRK3; -.
DR DMDM; 45593724; -.
DR CPTAC; non-CPTAC-6010; -.
DR CPTAC; non-CPTAC-6011; -.
DR EPD; Q8IV63; -.
DR jPOST; Q8IV63; -.
DR MassIVE; Q8IV63; -.
DR MaxQB; Q8IV63; -.
DR PaxDb; 9606-ENSP00000469880; -.
DR PeptideAtlas; Q8IV63; -.
DR ProteomicsDB; 70666; -. [Q8IV63-1]
DR ProteomicsDB; 70667; -. [Q8IV63-2]
DR ProteomicsDB; 70668; -. [Q8IV63-3]
DR Pumba; Q8IV63; -.
DR TopDownProteomics; Q8IV63-1; -. [Q8IV63-1]
DR Antibodypedia; 18806; 112 antibodies from 26 providers.
DR DNASU; 51231; -.
DR Ensembl; ENST00000316763.8; ENSP00000324636.2; ENSG00000105053.11. [Q8IV63-1]
DR Ensembl; ENST00000377011.6; ENSP00000366210.1; ENSG00000105053.11. [Q8IV63-3]
DR Ensembl; ENST00000594092.5; ENSP00000472541.1; ENSG00000105053.11. [Q8IV63-2]
DR Ensembl; ENST00000594948.5; ENSP00000473171.1; ENSG00000105053.11. [Q8IV63-1]
DR Ensembl; ENST00000599538.5; ENSP00000469880.1; ENSG00000105053.11. [Q8IV63-1]
DR Ensembl; ENST00000601341.5; ENSP00000470156.1; ENSG00000105053.11. [Q8IV63-3]
DR GeneID; 51231; -.
DR KEGG; hsa:51231; -.
DR MANE-Select; ENST00000316763.8; ENSP00000324636.2; NM_016440.4; NP_057524.3.
DR UCSC; uc002prg.3; human. [Q8IV63-1]
DR AGR; HGNC:18996; -.
DR CTD; 51231; -.
DR DisGeNET; 51231; -.
DR GeneCards; VRK3; -.
DR HGNC; HGNC:18996; VRK3.
DR HPA; ENSG00000105053; Tissue enhanced (testis).
DR MIM; 619771; gene.
DR neXtProt; NX_Q8IV63; -.
DR OpenTargets; ENSG00000105053; -.
DR PharmGKB; PA134923990; -.
DR VEuPathDB; HostDB:ENSG00000105053; -.
DR eggNOG; KOG1164; Eukaryota.
DR GeneTree; ENSGT00940000158111; -.
DR InParanoid; Q8IV63; -.
DR OMA; YCMVKWL; -.
DR OrthoDB; 4064676at2759; -.
DR PhylomeDB; Q8IV63; -.
DR TreeFam; TF106473; -.
DR PathwayCommons; Q8IV63; -.
DR Reactome; R-HSA-202670; ERKs are inactivated.
DR SignaLink; Q8IV63; -.
DR SIGNOR; Q8IV63; -.
DR BioGRID-ORCS; 51231; 9 hits in 1193 CRISPR screens.
DR ChiTaRS; VRK3; human.
DR EvolutionaryTrace; Q8IV63; -.
DR GenomeRNAi; 51231; -.
DR Pharos; Q8IV63; Tbio.
DR PRO; PR:Q8IV63; -.
DR Proteomes; UP000005640; Chromosome 19.
DR RNAct; Q8IV63; Protein.
DR Bgee; ENSG00000105053; Expressed in sperm and 192 other cell types or tissues.
DR ExpressionAtlas; Q8IV63; baseline and differential.
DR Genevisible; Q8IV63; HS.
DR GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR GO; GO:0019903; F:protein phosphatase binding; IDA:MGI.
DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR GO; GO:0007519; P:skeletal muscle tissue development; IGI:FlyBase.
DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR InterPro; IPR011009; Kinase-like_dom_sf.
DR InterPro; IPR000719; Prot_kinase_dom.
DR InterPro; IPR026870; Zinc_ribbon_dom.
DR PANTHER; PTHR11909; CASEIN KINASE-RELATED; 1.
DR PANTHER; PTHR11909:SF99; INACTIVE SERINE_THREONINE-PROTEIN KINASE VRK3; 1.
DR Pfam; PF00069; Pkinase; 1.
DR Pfam; PF13240; zinc_ribbon_2; 1.
DR SMART; SM00220; S_TKc; 1.
DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Cytoplasm; Nucleotide-binding; Nucleus;
KW Phosphoprotein; Reference proteome; Transferase; Ubl conjugation.
FT CHAIN 1..474
FT /note="Serine/threonine-protein kinase VRK3"
FT /id="PRO_0000086808"
FT DOMAIN 166..457
FT /note="Protein kinase"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT REGION 41..152
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOTIF 49..64
FT /note="Nuclear localization signal"
FT /evidence="ECO:0000269|PubMed:14645249"
FT COMPBIAS 41..85
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 92..152
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 54
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 55
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:18669648"
FT MOD_RES 59
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:18669648,
FT ECO:0007744|PubMed:23186163"
FT MOD_RES 82
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:19690332,
FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT MOD_RES 83
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:19690332,
FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT ECO:0007744|PubMed:23186163"
FT MOD_RES 90
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:19690332"
FT MOD_RES 108
FT /note="Phosphoserine; by CDK5"
FT /evidence="ECO:0000269|PubMed:27346674"
FT MOD_RES 115
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:21406692"
FT MOD_RES 122
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:21406692"
FT VAR_SEQ 47..96
FT /note="Missing (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:14702039"
FT /id="VSP_043409"
FT VAR_SEQ 407..412
FT /note="FVDKPG -> LPWDSF (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_008544"
FT VAR_SEQ 413..474
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_008545"
FT VARIANT 59
FT /note="S -> F (in dbSNP:rs2033262)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041295"
FT VARIANT 105
FT /note="P -> T (in dbSNP:rs11547882)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041296"
FT VARIANT 170
FT /note="S -> P (in dbSNP:rs11547881)"
FT /id="VAR_051682"
FT VARIANT 171
FT /note="F -> L (in dbSNP:rs11547883)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041297"
FT VARIANT 188
FT /note="T -> A (in dbSNP:rs11879620)"
FT /id="VAR_051683"
FT VARIANT 268
FT /note="S -> L (in dbSNP:rs10410075)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041298"
FT VARIANT 288
FT /note="C -> Y (in dbSNP:rs10409482)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041299"
FT VARIANT 304
FT /note="H -> L (in dbSNP:rs35261919)"
FT /id="VAR_051684"
FT VARIANT 370
FT /note="R -> C (in dbSNP:rs35331034)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041300"
FT VARIANT 371
FT /note="S -> G (in dbSNP:rs56407496)"
FT /evidence="ECO:0000269|PubMed:17344846"
FT /id="VAR_041301"
FT MUTAGEN 108
FT /note="S->A: Unable to be phosphorylated by CDK5."
FT /evidence="ECO:0000269|PubMed:27346674"
FT MUTAGEN 203
FT /note="K->E: Complete loss of kinase activity."
FT /evidence="ECO:0000269|PubMed:25899223"
FT CONFLICT 161
FT /note="K -> E (in Ref. 2; AAP47180)"
FT /evidence="ECO:0000305"
FT HELIX 142..148
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 157..159
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 165..175
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 178..185
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 200..206
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 211..221
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 224..233
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 246..250
FT /evidence="ECO:0007829|PDB:2JII"
FT TURN 251..253
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 254..260
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 266..272
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 274..276
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 280..299
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 311..315
FT /evidence="ECO:0007829|PDB:2JII"
FT STRAND 318..324
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 327..329
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 335..337
FT /evidence="ECO:0007829|PDB:2JII"
FT TURN 354..356
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 359..362
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 369..385
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 391..393
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 397..409
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 426..436
FT /evidence="ECO:0007829|PDB:2JII"
FT HELIX 446..459
FT /evidence="ECO:0007829|PDB:2JII"
SQ SEQUENCE 474 AA; 52881 MW; 86B9B91050A7F0CC CRC64;
MISFCPDCGK SIQAAFKFCP YCGNSLPVEE HVGSQTFVNP HVSSFQGSKR GLNSSFETSP
KKVKWSSTVT SPRLSLFSDG DSSESEDTLS SSERSKGSGS RPPTPKSSPQ KTRKSPQVTR
GSPQKTSCSP QKTRQSPQTL KRSRVTTSLE ALPTGTVLTD KSGRQWKLKS FQTRDNQGIL
YEAAPTSTLT CDSGPQKQKF SLKLDAKDGR LFNEQNFFQR AAKPLQVNKW KKLYSTPLLA
IPTCMGFGVH QDKYRFLVLP SLGRSLQSAL DVSPKHVLSE RSVLQVACRL LDALEFLHEN
EYVHGNVTAE NIFVDPEDQS QVTLAGYGFA FRYCPSGKHV AYVEGSRSPH EGDLEFISMD
LHKGCGPSRR SDLQSLGYCM LKWLYGFLPW TNCLPNTEDI MKQKQKFVDK PGPFVGPCGH
WIRPSETLQK YLKVVMALTY EEKPPYAMLR NNLEALLQDL RVSPYDPIGL PMVP
//
